During Montauk AI’s recent webinar, Operate, Optimize, Exit, one message came through clearly: in home-based care, clinical quality is not just a compliance issue. It is a driver of enterprise value, a source of buyer confidence, and one of the clearest ways operators can strengthen transaction outcomes before going to market.
That idea sat at the center of the conversation between Jarrett Bauer, CEO of Montauk AI, and Brian Mills, Senior Vice President of Growth at The Pennant Group. While many conversations around home health and hospice valuation focus heavily on revenue growth, EBITDA, and referral trends, this discussion made clear that the strongest businesses are not judged on financial performance alone.
They are also judged on the strength of their clinical operation, the integrity of their documentation, and the degree to which quality is embedded into the business itself.
Clinical Quality Is Part of the Value Creation Strategy
Jarrett framed the gap directly. He explained that one of the core problems Montauk AI set out to solve is that, when companies are selling, “clinical results and clinical excellence” are often not part of the conversation. In home-based care, that is a major miss.
If the product is care delivered in the home, then the quality of that care should have a direct bearing on how the company is valued. Buyers are not simply paying for current earnings. They are paying for the sustainability of those earnings, the credibility of the operating model, and the likelihood that performance will hold up after a transaction closes.
That is why clinical quality belongs in the valuation conversation. It is not an isolated operating issue sitting off to the side of the business. It is part of the business.
It shapes how buyers assess durability, transferability, and risk. In that sense, clinical quality is not just about protecting downside. It is part of how value is created in the first place.
Why Buyers See Clinical Quality as a Core Transaction Metric
Brian reinforced that point from the buyer side. When discussing the operational metrics that matter most before an acquisition, he was direct: “clinical quality is going to be the most important factor, really.”
That is a powerful statement because it changes how operators should think about what drives valuation. Strong revenue and healthy margins matter, but they do not stand on their own.
If buyers see weak documentation, underlying clinical issues, or patterns that suggest future compliance or operational risk, the financial story becomes less convincing.
The webinar also made clear that buyers evaluate clinical quality as part of a broader framework for business quality. Brian described Pennant’s “four cornerstones” as financial, clinical, culture, and community.
Clinical quality is not treated as an afterthought. It is one of the core dimensions buyers use to determine whether a business is sustainable, trustworthy, and worthy of long-term investment.
For owners, that is an important takeaway. A company may look attractive on paper, but sophisticated buyers want to know whether the operation beneath the numbers is just as strong.
Clinical Diligence Is Where Valuation Gets Confirmed or Questioned
One of the clearest insights from the webinar was that clinical diligence is often where the value story either holds up or starts to come under pressure.
Jarrett emphasized this directly when he said, “the clinical diligence piece is so big.” He noted that it is one of the reasons deals get hung up late in the process, especially when sellers wait too long to address it.
Many owners know their EBITDA, understand their margin profile, and can speak to top-line performance. But if clinical readiness has not been evaluated with the same seriousness, it can become a major source of friction just when momentum matters most.
Brian added an important nuance when he said, “it’s more than just saying, ‘I had a clean survey.’”
A clean survey is positive, but it is not enough to carry the full clinical story in a transaction. Buyers are going deeper. They are looking at documentation integrity, technical accuracy, chart quality, patterns in clinical performance, and whether there are issues that could surface after closing.
In other words, clinical diligence is where trust is either reinforced or weakened. It is where buyers determine whether the company’s reported performance is supported by a clinically sound foundation.
That has direct implications for value, leverage, and certainty to close.
Strong Clinical Quality Does More Than Reduce Risk
A key reason this matters so much is that clinical quality does more than reduce downside. It can actively improve transaction outcomes.
A business with strong chart discipline, reliable documentation, and consistent clinical performance is easier to diligence. It is easier to trust. It is easier to integrate. It is easier to believe in.
Those advantages matter in a process. They reduce uncertainty, improve buyer confidence, and help preserve credibility through diligence.
That is especially relevant in today’s home-based care environment, where quality measures are becoming more visible and more consequential.
Brian pointed to metrics like star ratings, scorecards, and the growing importance of value-based purchasing as examples of why clinical performance is becoming increasingly relevant in how businesses are assessed.
For sellers, that is a meaningful shift. Clinical quality should not be viewed only as a compliance function or a backend operational concern.
It can strengthen enterprise value by making the business more defensible, more durable, and more attractive to high-quality buyers.
Clinical Excellence Can Support Higher Enterprise Value
Jarrett pushed this point even further by connecting clinical quality directly to valuation. He said that when owners light up talking about their clinical results, that is often a sign of a stronger company, and that “those clinical results should be monetized too for more valuation at the end.”
That is one of the most important takeaways from the webinar.
Too often, owners spend years focused on growth, reimbursement pressure, labor, and margin management while treating clinical quality as something operationally essential but disconnected from enterprise value.
The conversation between Jarrett and Brian challenged that assumption. Clinical excellence is not just about avoiding a problem in diligence. It is part of what makes a business more valuable.
A company that can demonstrate strong care delivery, clean documentation, and a clinically sound operating model is not just better prepared for a transaction.
It is showing buyers that the business is high quality in a way that supports a stronger multiple, a smoother diligence process, and a more credible long-term story.
That is what makes clinical quality a value driver.
What Operators Should Do Before Going to Market
The webinar also offered practical guidance for operators who want to act on this now.
Brian recommended some form of regular internal audit or “triple check” process to catch technical errors before a buyer does.
That means reviewing whether signatures are complete, whether face-to-face documentation is in order, whether charts are telling the right story, and whether there are patterns that deserve deeper scrutiny.
This is not glamorous work, but it is high-value work.
Businesses that know what a buyer is likely to find before the buyer looks are in a much stronger position than businesses hoping diligence goes well.
For home health, hospice, and home care operators, the practical takeaway is clear:
- Do not wait until you are preparing for a sale to get serious about clinical quality
- Strengthen internal audits
- Review charts regularly
- Understand your quality metrics
- Build documentation excellence into the culture of the organization
- Treat clinical readiness with the same seriousness as financial readiness
Owners who do that are not just reducing risk. They are building a stronger company and improving the odds of a better outcome when the time comes to explore a transaction.
Final Takeaway
The clearest lesson from Montauk AI’s Operate, Optimize, Exit webinar is that clinical quality is not just part of delivering better care. It is part of building a more valuable business.
It supports buyer confidence. It reduces surprise in diligence. It reinforces the credibility of the financial story. And it can directly strengthen transaction outcomes by making a company more defensible, more transferable, and more attractive in the market.
As Jarrett Bauer and Brian Mills made clear throughout the discussion, the strongest home-based care businesses are not defined by revenue alone.
They are defined by the quality of the operation underneath it.
In that sense, clinical quality is not simply a compliance requirement. It is a value creation lever, and one of the clearest ways operators can protect and enhance enterprise value before going to market.